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Abstract
Background: Ischemic stroke is a common leading cause of death and disability with lack of effective therapies. In
this study, T3 was intra-ventricularly injected to evaluate gene expression and protein concentration of and brain-
derived neurotrophic factor (BDNF) and Glial cell-derived neurotrophic factor (GDNF) in hippocampal CA1 region in
rat model of brain ischemia/reperfusion (I/R).
Methods: In this study, transient middle cerebral artery occlusion (tMCAo) was used as model of ischemic brain
stroke. Rats were randomly divided in four groups of Co, Sh, tMCAo and tMCAo + T3. Then, a single dose of intra-
ventricular T3 was administered via a Hamilton syringe. Passive avoidance test was used as behavioral
investigations. After 21 days, the animals were sacrificed and their brains were used for molecular and
histopathological studies.
Results: T3 significantly improved the learning and memory compared with tMCAo group according to Morris
water maze findings (P < 0.05). Step-through latency (STL) significantly decreased in tMCAo group (P < 0.05). There
were significant increase in the STL of T3 group compared with tMCAo group (P < 0.05).A significant reduction in
BDNF mRNAs and protein levels were observed in the tMCAo compared with Co and Sh group (P < 0.05). A
significant increase of BDNF and GDNF mRNAs and proteins was recorded in tMCAo + T3 group compared with Co,
Sh and tMCAO groups (P < 0.05).
Conclusions: The results of current study demonstrated that T3 had therapeutic effects on cerebral ischemic stroke
by increasing the neurotrophic factors (BDNF, GDNF) in CA1 region of hippocampus.
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Background
Stroke is considered as one of the most leading cause of
long-term disability and around the world [1]. Disrup-
tion of blood flow in the main brain blood supplying ar-
teries such as middle cerebral artery (MCA) is an
important reason for ischemic stroke by induction of
hypoxia and glucose deprivation [2]. A complex series of
biochemical and molecular mechanisms including exci-
totoxic glutamatergic signaling, outburst of reactive oxy-
gen species (ROSs), over-production of inflammatory
mediators induce the pathogenesis of cerebral ischemia
by sudden death of a portion of neurons which leading
wide range of neurological defects [3–5]. It was shown
that among brain neurons, pyramidal neurons of hippo-
campal CA1 region are sensitive to ischemia condition
[6]. These neurons play critical roles in learning and
memory functions. Passive avoidance memory impair-
ment following brain ischemia is associated with degen-
eration of pyramidal neurons [7].
The lack of successful therapies leads to high mortality
and poor prognosis of patients with brain ischemia [8].
Although, the early thrombolytic therapies were sug-
gested to restoring the blood flow, reperfusion itself ex-
acerbate injury in the infarct core, leading condition
known as cerebral ischemia/reperfusion (I/R) injury [9,
10]. Up to now, therapeutic agents with different mech-
anism of anti-apoptosis [11, 12], antioxidant [13], anti-
inflammation [14] have been evaluated in animal models
following the brain ischemia. Recent studies confirmed
that thyroid hormones (THs) have broad neuroprotec-
tive effects on the nervous system [15].
THs (triiodothyronine [T3] and thyroxine [T4]) are es-
sential for brain development and morphogenesis, as
mental retardation can be observed in cases with con-
genital hypothyroidism [16, 17]. The anti-edema proper-
ties of THs in transient middle cerebral artery occlusion
(tMCAo) model of ischemic brain have been confirmed
[18]. T3 is less than T4 but more active form of THs
than T4 [19]. Moreover, a specific transporter known as
monocarboxylate 8 (MCT8) transfers T3 through blood
brain barrier (BBB) [20]. The genomic actions of T3 are
related to binding of this molecule to a specific receptor,
known as thyroid hormone receptors (THRs). THRs are
associated with the level of local expression of T3 and
THRs by acting as hormone-inducible transcription fac-
tor [21]. The neuroprotective effects of non-genomic T3
are induced though activation of nitric oxide and vaso-
dilation [22]. The neuroprotective benefits of THs estab-
lished prior to its neurological insult. THs can control
glutamate production, decrease oxidative stress and meta-
bolic demands of neurons [23]. Also, the neuroprotective
effects of T4 are associated with increasing the neuro-
trophic factors (NFs) such as brain driven neurotrophic
factor (BDNF) and glial cell-derived neurotrophic factor
(GDNF). Moreover, it is probably related to anti-apoptotic
and anti-inflammatory mechanisms [24].
BDNF is one of the most critical growth factors with
positive effects on the survival and maintenance of neur-
onal functions in the central nervous system. This factor
can induce the differentiation of neurons via stimulating
the receptor kinases [25]. Previously, it has been demon-
strated that intravenous administration of BDNF reduces
the infarct size following brain ischemia [26, 27]. GDNF,
with trophic activities on dopaminergic neurons, has
been shown to have neuroprotective impacts after ische-
mic brain injury [28].
As the strong neuroprotective property of T3 was dis-
cussed above, a single dose of T3 was selected and intra-
ventricularly injected after 24 h of ischemia reperfusion
as a therapeutic approach to attenuate exacerbation of
transient middle cerebral artery occlusion (tMCAo)
model of ischemia. Particularly, following endpoints
were examined in this investigation: (1) behavioral alter-
ation, (2) neurotrophic factors (BDNF, GDNF) expres-
sion and (3) dark neurons in histopathological studies
(H&E and Nissl staining).
Methods
Animals
Eighty male Wistar rats (26–28 months classified as old)
weighting 270–320 g were housed in a condition with
standardized temperature, humidity and 12 h light/dark
cycle and kept in the cages with free access to food and
water. The animals were kept in animal room and cared
in accordance with the guidelines of Tehran University
of medical sciences on animal care and approved by
Animal Ethics Committee of this university.
Transient middle cerebral artery occlusion (tMCAo)
Focal cerebral ischemia was induced using in the left
hemisphere tMCAo method. Anesthesia was induced
with 5.0% isoflurane (Baxter International) and spontan-
eously inhaled with 1.0–2.0% isoflurane in air via a
mask. During the procedure, the body core temperature
was maintained at 37°C with a recirculation pad and K
module and controlled via an intra-rectal temperature
probes and blood flow was monitored by Laser Doppler
flowmeter (Moor Instruments). A midline neck incision
was applied during the operation time to expose the left
common carotid artery (CCA). Then, CCA was dissected
from surrounding fascia and adjacent vagus nerve to
find its bifurcation. Then, the internal carotid artery
(ICA) was carefully isolated to conduct the monofila-
ment. An intraluminal 4–0 nylon monofilament (Doccol
Co., USA) was used to occlude the medial carotid artery
(MCA). This filament was inserted into the CCA and
conducted into ICA to block the origin of the MCA. To
apply the sham operation, the surgery was performed
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and the filament was inserted into the ICA and immedi-
ately withdrew.
Animal groups and treatments
Rats were randomly allocated to the following groups:
- Control group (Co): The normal rats without any
procedure and intracerebroventricular (ICV) injection
of solvent (phosphate buffered saline [PBS] with
maximum dose of 0.01% dimethyl sulfoxide [DMSO])
at the same time of tMCAo + T3 group.
- Sham group (Sh): Sham-operated rats with ICV injec-
tion of solvent at the same time of tMCAo +T3 with
group
- tMCAo group: Rats were subjected to occlusion for 1
h followed by 24 h reperfusion and solvent at the
same time of tMCAo + T3 with group
- tMCAo + T3 group: Rats were subjected to occlusion
for 1 h and a single dose ICV of T3 (25 ug/kg body)
was administered 24 after reperfusion [20]. T3 was
dissolved in DMSO and diluted with PBS to reach
maximum dose of 0.01% DMSO and a total volume
of 5 ul was used for ICV injection. T3 or solvent was
immediately injected using Hamilton syringe into the
left cerebral ventricle (according to the following
coordinates: bregma: AP = −0.9 mm, ML = -1.8 mm
(midline), and DV = 3.5 mm deep from the dura) [29].
The same volume of solvent was used in the other
groups.
Body weight evaluation
The body weight of animals was investigated on initial
day of study (X1) and 1st, 7th and 21st (Xi) days follow-
ing the injection. Then, the percentage of body weight
change (BWC) was calculated by following formula:
BWC %ð Þ ¼ X1‐Xið Þ= X1þ Xið Þ  100
On day 21, the animals were sacrificed and hippocam-
pal CA1 region was harvested to study the gene expres-
sion (n = 4 rats in each group) and protein concentration
(n = 4 rats in each group). Then, total brain was removed
for histopathological studies (n = 4 rats in each group).
Behavioral study
Morris water maze
Morris water maze tasks mainly include orientation
navigation and space exploration trials. The water maze
apparatus consisted of circular tank (diameter: 130 cm,
depth: 60 cm) filled with opaque water (depth: 30 cm,
temperature: 25 ± 3°C). The pool was divided into four
sections and a camera attached to a computer was
placed above the center of apparatus.
A safe platform was submerged in the pool approxi-
mately 2 cm below water surface, 30 cm from the wall
of the pool in the center of the northeast quadrant. Each
trial was videotaped and the animals’ movement tracked
using a computer assisted tracking system. Testing
began 21 days post injury and the rats were examined
for 5 days with four trials for each session. Parameters
for the test were time to find the platform, distance trav-
eled to find the platform, time spent in platform quarter
and distance traveled in platform quarter. The 5 sessions
was a spatial probe trial in which the platform was re-
moved and the rats were placed into the core of the pool
and allowed to swim for 90 s. This test measures swim
strategies and working (short-term, trial-to-trial) and ref-
erence (longer-term, day-to-day) memory.
Step-through passive avoidance test
Passive avoidance learning test was used for evaluation
of the learning and memory performance in the rats (n
= 8 rats). The apparatus was a shuttle-box consists of
two separate illuminated and dark chambers. These
chambers were connected through a guillotine door. To
deliver electric shocks, the base of the both chambers
was made from still grill. The different phases of study
were as below:
Step 1: adaptation and habitation
One day before the tMCAo induction, adaptation phase
was performed for each rat. In a single trail, each rat was
placed in the illuminated chamber and allowed to enter
the dark chamber. One h later, rat was put into the illu-
minated chamber while its back was to the guillotine
door. After 5 s of habituation, the guillotine door was
simultaneously opened and rat was allowed entering the
dark chamber. The latency time (LT1) to enter into the
dark chamber was recorded. The rats with more than
100 s LT1 were excluded.
Step 2: training
One hour before the surgery, rat was placed into the il-
luminated chamber. After rat entered the dark chamber,
the door was closed as soon as the rat stepped into the
dark chamber and an electric foot shock (75 V, 0.2 mA,
50 Hz) was immediately delivered to the floor grids for 3
s. The latency time (LT2) was taken in this step (in sec-
ond). Then, the rat was removed from the dark chamber
and placed into the home cage. This procedure was re-
peated every 2 min for three times. If the rats did not
enter the dark chamber, the latency time was recorded
as 120 s.
Step 3: retention trial
In the acquisition trial, the time of retention latency
(step-through latency [STL]) to enter the dark chamber
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was recorded in the same way without foot shock four
times after 24 h of reperfusion: 1) STL1: Step-through
latency 24 h after T3 administration,2) STL3: Step-
through latency 3 days after solvent and T3 administra-
tion, 3) STL7: Step-through latency 3 days after solvent
and T3 administration and 4) STL21: Step-through la-
tency 21days after solvent and T3 administration (As the
cut-off, the latency time was recorded up to a maximum
of 300 s) and the longest STL was recorded.
Total RNA extraction and quantitative real-time PCR
Twenty one day later, four rats in each group were used
for gene expression of BDNF and GDNF. The brain rap-
idly removed under anesthesia and placed in ice-cold
0.9% saline. Then, the coronal sections (1mm) were pre-
pared using a brain matrix. According to the stereo-
allocation atlas, left CA1 hippocampal region of rat was
quickly isolated under a dissecting microscope [30]. The
expression of BDNF and GDNF genes in hippocampal
CA1 region (n = 4 rats per group) was measured using
quantitative real time PCR. In this way, total RNA was
extracted by TriPure Isolation reagent (Takara Bio Inc.,
Otsu, Japan) according to manufacturer instruction.
Then, cDNA was synthesized from 1μg total RNA using
PrimeScript RT Reagent Kit (Takara Bio Inc., Otsu,
Japan) according to manufacturer guidlines. The relative
levels of BDNF and GDNF mRNAs were determined
using ABI PRISM 7500 real-time PCR system (Roche
Diagnostics, Germany). The primers were designed using
Allele ID software (version 6). The primer sequences were
as follow: BDNF, forward primer 5’-ATAATGTCT-
GACCCCAGTGCC-3’, and reverse primer 5’- CTGAGG-
GAACCCGGTCTCAT -3’, GDNF, forward primer: 5’-
GCGCTGACCAGTGACTCCAA -3’, and reverse primer:
5’- GCGACCTTTCCCTCTGGAAT-3’, the b-actin gene,
forward primer 5'- ACAACCTTCTTGCAGCTCCTC-3'
and reverse: 5'- CTGACCCATACCCACCATCAC-3'(con-
sidered as the internal control standard). Quantitative
real-time PCR was performed in a Cycler (Light Cycler
2.0, Roche) using SYBR Green (Takara Bio Inc., Otsu,
Japan). The thermal cycling conditions were 95°C for 30 s
as initial activation step. It was followed by 40 cycles of
denaturation step including 95°C for 5 s which combined
with annealing/extension step at 60 °C for 20 s. The
threshold cycles (Ct), chosen from the linear range, was
used for each sample and converted to a starting quantity.
Concentration of BDNF and GDNF proteins in CA1 region
The protein concentrations of BDNF and GDNF in CA1
region of four rats (in each group) were evaluated using
ABCAM ELISA kits and their manufacturer's guidelines.
Hippocampal CA1 region was harvested as described
above. Briefly, lysis buffer containing 137 mM NaCl, 20
mM Tris–HCl (pH 8.0), glycerol (10%), Igepal (1%), 0.5
mM sodium vanadate, 1 mM PMSF, 0.1 mM EDTA and
0.1 mM EGTA was used for homogenizing CA1 region
of hippocampus (n = 4 rats per group). Then the homog-
enized tissue was centrifuged at 14,000 rpm at 4 °C for 3
min. The supernatant was diluted using sample buffer
and incubated on 96-well flat-bottom plates. These
plates were previously coated with anti-BDNF and anti-
GDNF monoclonal antibodies. After blocking, plates
were subsequently incubated with polyclonal anti-rabbit
antibody for 2 h and horseradish peroxidase for 1 h. For
calculating the concentration, the color reaction with
tetramethyl benzidine was quantified in a plate reader at
450 nm.
Histopathological study
Four rats in each group were selected for light micros-
copy study. Under anesthesia, the brains were perfused
through a transcardial perfusion of 200 mL normal sa-
line followed by 200 mL of 4% paraformaldehyde (PFA,
sigma) in 0.1 M phosphate buffer (pre-fixation). The
brains were removed and cut coronally into 3–5 mm-
thick sections included the dorsal hippocampus. Then
the sections were post-fixed in 10% formalin 72 h at 4°C.
For light microscopy observation, the samples were em-
bedded in paraffin and 5 μm coronal sections (one from
each five sections) were prepared using a rotary micro-
tome (Leica Biosystems, Milan, Italy). The tissue sections
stained with Hematoxylin and eosin (H&E) and Nissl
methods (0.5% cresyl violet). In this way, the sections
were dehydrated through graded alcohols (70, 80, 90,
and 100% × 2), mounted in Canada balsam, and then an-
alyzed using a light field microscope (Olympus, CX31,
Tokyo, Japan). The intact and ischemic cells (dark neu-
rons) in CA1 field were counted in the × 400 images pre-
pared using a camera connected to the microscope [31].
Statistical analysis
Results are expressed as mean ± S.E.M. The data were
analyzed statistically by t-test and one way analysis of
variance (ANOVA) with Tukey's post hoc statistical
tests. Non-parametric test (Behavioral results were ana-
lyzed statistically using Kruskal-Wallis Test (nonpara-
metric ANOVA) and Dunn's Multiple Comparisons for
post-test. The significant level was set at P < 0.05.
Results
Effects of T3 on the percentage of body weight change in
rats with tMCAo
The effect of intraventricular injection of T3 on percent-
age of body weight change (BWC) was evaluated after
transient focal cerebral ischemia/reperfusion model of
rat on day 1, 7 and 21.
According to results, the mean BWC was significantly
difference in the studied groups (P < 0.05, Fig. 1). Also, a
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significant decrease was recorded in the BWC of tMCAo
and tMCAo + T3 groups compared with Co group on
day 1, 7 and 21 after injection (P < 0.05, Fig. 1). In
addition the BWC of tMCAo + T3 group significantly in-
creased compared tMCAo group on day 21 after injec-
tion (P < 0.05, Fig. 1).
Effects of ICV injection of T3 on learning and memory in
rats with tMCAo
Results of Morris water maze
Treatments with T3 could improve spatial learning and
memory in experimental group. According to Fig. 2, the
mean latency (duration) time to reach the hidden plat-
form (P > 0.05, Fig. 2a) and distance traveled in the Mor-
ris water maze (P > 0.05, Fig. 2b) were evaluated in
tMCAo and tMCAo + T3 groups. However, significant
decrease in the mean latency (duration) time to reach
the hidden platform (P > 0.05, Fig. 2a) and distance trav-
eled in Morris water maze (P > 0.05, Fig. 2b) was ob-
served in T3 treated group compared to tMCAo group
(P > 0.05, Fig. 2a and b).
Moreover, the probe trial revealed that tMCAo and drugs
treated groups spent significantly less time (P > 0.05, Fig. 1c)
and distances in the platform quadrant (P > 0.05, Fig. 2d)
compared to control and sham groups (Co and Sh). Rats in
tMCAo +T3 group spent significantly more time (P > 0.05,
Fig. 2c) and distance in the platform quadrant (P > 0.05, 2d)
compared to tMCAo group.
Effects of ICV injection of T3 on STL in the passive
avoidance test in rats with tMCAo
There was no significant difference in the LT1 and LT2
of different groups (Fig. 3a). There was significant differ-
ence in the STL of study groups at different evaluation
times (p < 0.05, Fig. 3b). There was significant reduction
in the STL of tMCAo group compared with Sh and Co
groups on day 1, 3, 7 and 21 (p < 0.05, Fig. 3b). A signifi-
cant decrease was observed in the STL of tMCAo + T3
group compared with Sh and Co groups on day1, 3, 7
and 21 (p < 0.05, Fig. 3b). Moreover, a significant
increase was shown in the STL of group with T3 admin-
istration compared with tMCAo on day 1, 3, 7 and 21
(p < 0.05, Fig. 3b).
Effects of T3 on BDNF and GDNF gene expression in
hippocampal CA1 region in rats with tMCAo
According to the Fig. 3a, there were significant differ-
ences in the gene expression of BDNF and GDNF be-
tween study groups. A significant decrease was observed
in the gene expression of BDNF in tMCAo group com-
pared with Co and Sh groups (p < 0.05, Fig. 4a). There
was significant increase in the gene expression of BDNF
Fig. 1 Effects of ICV injection of T3 on percentage of Body weight change following brain ischemia in rat on day 1, 7 and 21. *p < 0.05 compared
to Co and Sh groups; #p < 0.05 compared to tMCAo group. Co: normal group with ICV injection of solvent, Sh: sham operated group with ICV
injection of solvent; tMCAo: Ischemia induction group with ICV injection of solvent, tMCAo + T3: Ischemia induction group with ICV injection
of T3
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Fig. 2 Effects of ICV injection of T3 on spatial memory and learning following brain ischemia in rat. a Mean latency to platform, b Mean Distance
traveled to platform (c) time spent in the platform and (d) distance spent in the platform. * p < 0.05 compared to Co and Sh groups; #p < 0.05
compared to tMCAo group. Co: normal group with ICV injection of solvent, Sh: sham operated group with ICV injection of solvent; tMCAo:
Ischemia induction group with ICV injection of solvent, tMCAo + T3: Ischemia induction group with ICV injection of T3
Fig. 3 Effects of ICV injection of T3 on STL in the passive avoidance test following brain ischemia in rat. a LT1: Latency time at 24 h before to ischemia;
LT2: Latency time at 1h before to ischemia; b STL1: Step-through latency 24 h after solvent and T3 administration; STL3: Step-through latency 3 days
after solvent and T3 administration, STL7: Step-through latency 7 days after solvent and T3 administration, STL21: Step-through latency 21 days after
solvent and T3 administration, *p < 0.05 compared to Co and Sh groups; #p < 0.05 compared to tMCAo group. Co: normal group with ICV injection of
solvent, Sh: sham operated group with ICV injection of solvent; tMCAo: Ischemia induction group with ICV injection of solvent, tMCAo + T3: Ischemia
induction group with ICV injection of T3
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in tMCAo + T3 group compared with Co, Sh and
tMCAo groups (p < 0.05, Fig. 4a). Furthermore, a signifi-
cant increase was recorded in the gene expression of
GDNF in tMCAo + T3 group compared with Co, Sh and
tMCAo groups (p < 0.05, Fig. 4b).
Effects of T3 on BDNF and GDNF protein concentration in
hippocampal CA1 region in rats with tMCAo
According to ELISA results, the protein concentration
of BDNF was reduced in tMCAo group compared
with Co and Sh groups (p < 0.05, Fig. 5a). There was
significant increase in the concentration of BDNF
protein in tMCAo + T3 group compared with Co, Sh
and tMCAo groups (p < 0.05, Fig. 5a). The protein
concentration of GDNF significantly was reduced in
tMCAo group compared with Co and Sh groups (p <
0.05, Fig. 5b). Moreover, a significant increase was
observed in the protein concentration of GDNF in
tMCAo + T3 group compared with Co, Sh and
tMCAo groups (p < 0.05, Fig. 5b).
Effects of T3 on the number of dark neurons in
hippocampal CA1 region of in rats with tMCAo
The number of dark neurons was calculated in CA1 re-
gion of hippocampus in the study groups. There was sig-
nificant increase in the mean number of dark neurons in
tMCAo and tMCAo groups compared with Co and Sh
Fig. 4 Effects of ICV injection of T3 on neurotrophic factor gene expression of hippocampal CA1 region following brain ischemia in rat. a BDNF
gene expression, b GDNF gene expression. *p < 0.05 compared to Co and Sh groups; #p < 0.05 compared to tMCAo group. Co: normal group
with ICV injection of solvent, Sh: sham operated group with ICV injection of solvent; tMCAo: Ischemia induction group with ICV injection of
solvent, tMCAo + T3: Ischemia induction group with ICV injection of T3
Fig. 5 Effects of ICV injection of T3 on neurotrophic factor protein concentration of hippocampal CA1 rejoin following brain ischemia in rat. a
BDNF and b GDNF proteins. *p < 0.05 compared to Co and Sh groups; #p < 0.05 compared to tMCAo group. Co: normal group with ICV injection
of solvent, Sh: sham operated group with ICV injection of solvent; tMCAo: Ischemia induction group with ICV injection of solvent, tMCAo + T3:
Ischemia induction group with ICV injection of T3
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groups (p < 0.05, Fig. 6). A significant decrease was re-
corded in the mean number of dark neurons in tMCAo+
T3 compared with tMCAo group (p < 0.05, Fig. 6).
Discussion
In this study, tMCAo model was carried out for experi-
mental evaluations. Different animal models were estab-
lished to study the brain ischemia in the literature.
Transients MCA occlusion (tMCAo) is a rodent model of
ischemia that is widely used to analyze the mechanisms
triggered by ischemic stroke and study the potential ther-
apies [32, 33]. In brain ischemia, a cascade of pathological
events and subsequent neuronal damages are induced
within minutes of its onset [34]. These pathological events
are associated with a complex process involving metabolic
dysfunction, inflammation, neuronal necrosis and apop-
tosis, microvascular and endothelial dysfunction following
an impaired blood flow [35]. Moreover, the neurons of
some regions are susceptible to cerebral ischemia. The
most common affected regions are cerebral cortex and
striatum, while secondary cell death occurs in the CA1 re-
gion of hippocampus within 2–4 days after transient brain
ischemia [36, 37]. These pathological events and following
disabilities are confirmed in tMCAo model of brain ische-
mia stroke [38, 39].
The effects of different therapies with various mecha-
nisms have been evaluated on the brain ischemia models
to manage the pathogenesis and outcomes of this condi-
tion [11–14]. THs (T3 and T4) are essential for develop-
ment, growth and metabolism especially in nervous
system [19]. In addition, T3 plays important role in
neurogenesis in the early stages of brain development
[40, 41]. This active form of THs can bind to thyroid re-
ceptors (TRs) with much affinity than T4 which is more
abundant [42]. In the current study, the effects of T3 (a
single dose of 25ug/Kg) were evaluated on tMCAo
model of ischemia in different aspects of behavioral, mo-
lecular and histopathological.
The finding of present study showed that the neuro-
trophins (BDNF and GDNF) expression pattern was
Fig. 6 Effects of ICV injection of T3 on pyramidal neurons of CA1 region of hippocampus following brain ischemia in rat. a Nissl staining (arrows:
dark neurons, ×400), b H&E staining (arrows: dark neurons, ×400), c Comparing the dark neuron number in different groups. *p < 0.05 compared
to Co and Sh groups; #p < 0.05 compared to tMCAo group. Co: normal group with ICV injection of solvent, Sh: sham operated group with ICV
injection of solvent; tMCAo: Ischemia induction group with ICV injection of solvent, tMCAo + T3: Ischemia induction group with ICV injection
of T3
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disrupted in CA1 region of hippocampus due to tMCAo.
This condition leads to sever deficits in expression of
these neurotrophins. The similar result was demon-
strated in recent study by Genovese et al. [24]. It was
shown that the morphological changes in hippocampus
were associated with regulation of mRNAs expression of
neurotrophins [43]. Administration of neurotrophic
factors following the brain ischemia was investigated in
different studies. In a review article, Chen et al [23]
showed that BDNF is a safe and potential agent with
neuroprotective properties against ischemic brain injury.
In addition, the neuroprotective effects of GDNF in the
ischemic brain was evaluated by Duarte et al [28].
Different mechanisms have been suggested for beneficial
effects of THs against neurological defects. The mechan-
ism and molecular basis of THs against the toxicity condi-
tions during the ischemia was investigated in different
studies. Their ability to induce hypothermia, anti-edema,
anti- apoptotic anti-inflammation and vasodilation acti-
vates are evaluated in different studies [15, 16, 22, 44].
THs regulate BDNF gene expression in different regions
during the development [45–47] and maturation [48] of
nervous system. Sui et al. [49] demonstrated that adminis-
tration of THs increased BDNF gene expression in normal
rat hippocampus by promoter-specific regulation of
BDNF. Accordingly, Campolo et al [44] showed that post
stroke ICV injection of T4 can increase BDNF and GDNF
RNA transcripts and protein levels in hippocampal CA1
region. In a similar study, by Genovese et al. [24], T4 (1.1
mg/100 g BW) effects on ischemia model of stroke follow-
ing reperfusion was evaluated. Their results revealed that
T4 has therapeutic effects on brain ischemia through anti-
apoptotic and anti-inflammatory mechanisms and regula-
tion of NFs (BDNF and GDNF) expression in brain tissue
in a rat model of acute ischemic stroke . It has been dem-
onstrated that activation of NFs via THs is associated with
their effects on transcriptional factors or epigenetic medi-
ated processes (a mechanism for covalent modifications of
the DNA or its related proteins without a change of DNA
sequence) [50–52].
According to the results of current study, it was
showed that the mean number of dark neurons was high
in hippocampus CA1 region following cerebral ischemia.
Moreover, the number of dark pyramidal neurons was
reduced in T3 treated group in comparison with ische-
mic group. In a study by Rami and Krieglstein [53], it
was shown that daily administration of T4 reduced hip-
pocampal neuronal damage following brain ischemia.
Their results indicated that neural density was increased
50% by T4 treatment compared with ischemic group
[53]. Losi et al. [54] reported that rat hippocampal
neurons were protected against glutamate toxicity by
non-genomic T3 administration. Thus, both non-
genomic and genomic mechanisms of T3 were involved
in the protection of neurons and glial cells against the
glutamate toxicity [44, 55, 56]. According to the results,
the survival effects of T3 in decreasing the dark neurons
may be associated with increasing NFs in CA1 region.
According to the Morris water maze and step-through
finding, it was demonstrated that a single dose of T3
(ICV injection) improved memory and learning in
treated group compared with ischemic group in short
and long times. Low T3 concentration introduced as a
strong predictor of stroke with a worse outcome accord-
ing to significant human clinical evidence. In other study
by Zhang et al. [57], it was suggested that low T3
level in the serum of patients with AIS was associated
with unfavorable neurological outcomes. Previously,
Hiroi et al. [22] evaluated the effects of T3 on transi-
ent cerebral ischemia in mice. They showed that a
single bolus infusion of T3 rapidly increased the acti-
vation of PI3-kinase/Akt pathways activity in the
brain, decreased cerebral infarct volume, and repaired
neurological deficit score. In addition, they showed
that T3 reduced blood pressure in focal cerebral is-
chemia via vasodilation mechanism related to eNOS
contribution [22]. So, the administration of T3 pre-
vented the worse outcomes of cerebral stroke in a
schemial model of stroke. In addition, the ICV injec-
tion dose of 25ug/Kg was confirmed that did not in-
duce thyro-toxicity in investigated animals in the
present study. Drover et al. [58] recorded that injec-
tion of T3 (250 μg/kg dose for 14 consecutive days)
was required after experimental hyperthyroidism in-
duction in mice.
Conclusion
According to these findings, it has been suggested that
presence of T3 in brain play an essential role for modu-
lation of NFs expression. The findings of current study
confirmed the greater survival of CA1 hippocampal neu-
rons in T3 treated animals via neurotrophic factors regu-
lation and provide evidence to stimulate clinical
development of T3 for use as effective therapy in ische-
mic brain stroke to reduce the cognitive impairment.
Abbreviations
BDNF: Brain-derived neurotrophic factor; GDNF: Glial cell-derived neuro-
trophic factor; I/R: Ischemia/reperfusion; LT: Latency time; MCA: Middle
cerebral artery; NFs: Neurotrophic factors; ROSs: Reactive oxygen species;
STL: Step-through latency; T3: Triiodothyronine; T4: Thyroxine; THRs: Thyroid
hormone receptors; THs: Thyroid hormones; tMCAo: Transient middle
cerebral artery occlusion
Acknowledgment
This study was performed at department of anatomy, school of medicine,
Tehran University of Medical Sciences
Funding
This study was supported by a grant (93-01-30-25144) from Tehran University
of Medical Sciences.
Mokhtari et al. DARU Journal of Pharmaceutical Sciences  (2017) 25:4 Page 9 of 11
Availability of data and materials
Not applicable.
Authors’ contributions
GH and TM carried out study concept and design, GH, MA, MG, FN and IR
carried out providing laboratory equipment, TM, GH and FN carried out
analysis and interpretation of data, TM carried out drafting of the manuscript,
GH, MA, FM and TR carried out critical revision of the manuscript for
important intellectual content, TM and FA carried out statistical analysis. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This animal study was approved by Animal Ethics Committee of Tehran
University of medical sciences.
Author details
1Department of Anatomy, School of Medicine, Tehran University of Medical
Sciences, Tehran, Iran. 2Department of Immunology, School of Medicine,
Tehran University of Medical Sciences, Tehran, Iran. 3Department of
Pharmacology, School of Medicine, Tehran University of Medical Sciences,
Tehran, Iran. 4Department of Neuroscience, School of Advanced
Technologies in Medicine, Tehran University of Medical Sciences, Tehran,
Iran.
Received: 28 July 2016 Accepted: 7 February 2017
References
1. Xiong D, Deng Y, Huang B, Yin C, Liu B, Shi J, et al. Icariin attenuates
cerebral ischemia–reperfusion injury through inhibition of inflammatory
response mediated by NF-κB, PPARα and PPARγ in rats. Int
Immunopharmacol. 2016;30:157–62.
2. Céspedes‐Rubio A, Jurado FW, Cardona‐Gómez GP. p120 catenin/αN‐
catenin are molecular targets in the neuroprotection and neuronal plasticity
mediated by atorvastatin after focal cerebral ischemia. J Neurosci Res. 2010;
88(16):3621–34.
3. Chan A, Yan J, Csurhes P, Greer J, McCombe P. Circulating brain derived
neurotrophic factor (BDNF) and frequency of BDNF positive T cells in
peripheral blood in human ischemic stroke: effect on outcome.
J Neuroimmunol. 2015;286:42–7.
4. Murray V, Norrving B, Sandercock P, Terént A, Wardlaw J, Wester P. The
molecular basis of thrombolysis and its clinical application in stroke. J Intern
Med. 2010;267(2):191–208.
5. Black JM, Hawks JH, Keene AM. Medical-surgical nursing: Clinical
management for positive outcomes. 2005.
6. Bin J, Wang Q, Zhuo Y-Y, Xu J-P, Zhang H-T. Piperphentonamine (PPTA)
attenuated cerebral ischemia-induced memory deficits via neuroprotection
associated with anti-apoptotic activity. Metab Brain Dis. 2012;27(4):495–505.
7. Karasawa Y, Araki H, Otomo S. Changes in locomotor activity and passive
avoidance task performance induced by cerebral ischemia in Mongolian
gerbils. Stroke. 1994;25(3):645–50.
8. Adams HP, Adams RJ, Brott T, Del Zoppo GJ, Furlan A, Goldstein LB, et al.
Guidelines for the early management of patients with ischemic stroke a
scientific statement from the stroke council of the american stroke
association. Stroke. 2003;34(4):1056–83.
9. Traystman RJ, Kirsch JR, Koehler RC. Oxygen radical mechanisms of brain injury
following ischemia and reperfusion. J Appl Physiol. 1991;71(4):1185–95.
10. McMichael M, Moore RM. Ischemia–reperfusion injury pathophysiology, part
I. J Vet Emerg Crit Care (San Antonio). 2004;14(4):231–41.
11. Xu X, Zhang S, Zhang L, Yan W, Zheng X. The Neuroprotection of puerarin
against cerebral ischemia is associated with the prevention of apoptosis in
rats. Planta Med. 2005;71(7):585–91.
12. Yu S-S, Zhao J, Zheng W-P, Zhao Y. Neuroprotective effect of 4-hydroxybenzyl
alcohol against transient focal cerebral ischemia via anti-apoptosis in rats.
Brain Res. 2010;1308:167–75.
13. Peeling J, Del Bigio MR, Corbett D, Green AR, Jackson DM. Efficacy of
disodium 4-[(tert-butylimino) methyl] benzene-1, 3-disulfonate N-oxide
(NXY-059), a free radical trapping agent, in a rat model of hemorrhagic
stroke. Neuropharmacology. 2001;40(3):433–9.
14. Beech JS, Reckless J, Mosedale DE, Grainger DJ, Williams SC, Menon DK.
Neuroprotection in Ischemia–Reperfusion Injury&colon; An Antiinflammatory
Approach Using a Novel Broad-Spectrum Chemokine Inhibitor. J Cereb Blood
Flow Metab. 2001;21(6):683–9.
15. Lin H-Y, Davis FB, Luidens MK, Mousa SA, Cao JH, Zhou M, et al. Molecular
basis for certain neuroprotective effects of thyroid hormone. Front Mol
Neurosci. 2011;4(29.10):3389.
16. De Escobar GM, Obregón MJ, Del Rey FE. Role of thyroid hormone during
early brain development. Eur J Endocrinol. 2004;151(Suppl 3):U25–37.
17. Crupi R, Paterniti I, Campolo M, Di Paola R, Cuzzocrea S, Esposito E.
Exogenous T3 administration provides neuroprotection in a murine model
of traumatic brain injury. Pharmacol Res. 2013;70(1):80–9.
18. Sadana P, Coughlin L, Burke J, Woods R, Mdzinarishvili A. Anti-edema action
of thyroid hormone in MCAO model of ischemic brain stroke: Possible
association with AQP4 modulation. J Neurol Sci. 2015;354(1):37–45.
19. Yen PM. Physiological and molecular basis of thyroid hormone action.
Physiol Rev. 2001;81(3):1097–142.
20. Mdzinarishvili A, Sutariya V, Talasila PK, Geldenhuys WJ, Sadana P.
Engineering triiodothyronine (T3) nanoparticle for use in ischemic brain
stroke. Drug Deliv Transl Res. 2013;3(4):309–17.
21. Minato K, Tomimatsu T, Mimura K, Jugder O, Kakigano A, Kanayama T, et al.
Hypoxic preconditioning increases triiodothyronine (T3) level in the
developing rat brain. Brain Res. 2013;1501:89–97.
22. Hiroi Y, Kim H-H, Ying H, Furuya F, Huang Z, Simoncini T, et al. Rapid
nongenomic actions of thyroid hormone. Proc Natl Acad Sci U S A. 2006;
103(38):14104–9.
23. Chen A, Xiong L-J, Tong Y, Mao M. The neuroprotective roles of BDNF in
hypoxic ischemic brain injury (Review). Biomed Rep. 2013;1(2):167–76.
24. Genovese T, Impellizzeri D, Ahmad A, Cornelius C, Campolo M, Cuzzocrea S,
et al. Post-ischaemic thyroid hormone treatment in a rat model of acute
stroke. Brain Res. 2013;1513:92–102.
25. Razavi S, Razavi MR, Zarkesh Esfahani H, Kazemi M, Mostafavi FS.
Comparing brain‐derived neurotrophic factor and ciliary neurotrophic
factor secretion of induced neurotrophic factor secreting cells from
human adipose and bone marrow‐derived stem cells. Dev Growth
Differ. 2013;55(6):648–55.
26. Schäbitz W-R, Schwab S, Spranger M, Hacke W. Intraventricular brain-derived
neurotrophic factor size after focal cerebral ischemia in rats. J Cereb Blood
Flow Metab. 1997;17(5):500–6.
27. Schäbitz W-R, Sommer C, Zoder W, Kiessling M, Schwaninger M, Schwab S.
Intravenous brain-derived neurotrophic factor reduces infarct size and
counterregulates Bax and Bcl-2 expression after temporary focal cerebral
ischemia. Stroke. 2000;31(9):2212–7.
28. Duarte EP, Curcio M, Canzoniero LM, Duarte CB. Neuroprotection by GDNF
in the ischemic brain. Growth Factors. 2012;30(4):242–57.
29. Paxinos G, Watson C. The rat brain in stereotaxic coordinates: hard cover
edition. 2006. The Netherlands: Academic Press, Elsevier.
30. Liu L, Li C-j, Lu Y, Zong X-g, Luo C, Sun J, et al. Baclofen mediates
neuroprotection on hippocampal CA1 pyramidal cells through the
regulation of autophagy under chronic cerebral hypoperfusion. Sci Rep.
2015;5:14474.
31. Atlasi MA, Naderian H, Noureddini M, Fakharian E, Azami A. Morphology of
Rat Hippocampal CA1 neurons following modified two and four-vessels
global ischemia models. Arch Trauma Res. 2013;2(3):124–8.
32. Sutherland BA, Neuhaus AA, Couch Y, Balami JS, DeLuca GC, Hadley G et al.
The transient intraluminal filament middle cerebral artery occlusion model
as a model of endovascular thrombectomy in stroke. J Cerebral Blood Flow.
2016;36(2):363-9.
33. Shahjouei S, Cai PY, Ansari S, Sharififar S, Azari H, Ganji S, et al. Middle Cerebral
Artery Occlusion Model of Stroke in Rodents. J Vasc Interv Neurol. 2016;8(5):1.
34. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an
integrated view. Trends Neurosci. 1999;22(9):391–7.
35. Mattson M, Duan W, Pedersen W, Culmsee C. Neurodegenerative disorders
and ischemic brain diseases. Apoptosis. 2001;6(1-2):69–81.
36. Butler TL, Kassed CA, Sanberg PR, Willing AE, Pennypacker KR.
Neurodegeneration in the rat hippocampus and striatum after middle
cerebral artery occlusion. Brain Res. 2002;929(2):252–60.
Mokhtari et al. DARU Journal of Pharmaceutical Sciences  (2017) 25:4 Page 10 of 11
37. Erfani S, Khaksari M, Oryan S, Shamsaei N, Aboutaleb N, Nikbakht F, et al. Visfatin
reduces hippocampal CA1 cells death and improves learning and memory
deficits after transient global ischemia/reperfusion. Neuropeptides. 2015;49:63–8.
38. Mao Y, Yang G-Y, Zhou L-F, Stern JD, Betz AL. Focal cerebral ischemia in the
mouse: description of a model and effects of permanent and temporary
occlusion. Mol Brain Res. 1999;63(2):366–70.
39. Hill WD, Hess DC, Carroll JE, Wakade CG, Howard EF, Chen Q, et al. The NF-κB
inhibitor diethyldithiocarbamate (DDTC) increases brain cell death in a transient
middle cerebral artery occlusion model of ischemia. Brain Res Bull. 2001;55(3):375–86.
40. Ambrogini P, Cuppini R, Ferri P, Mancini C, Ciaroni S, Voci A, et al. Thyroid
hormones affect neurogenesis in the dentate gyrus of adult rat.
Neuroendocrinology. 2005;81(4):244–53.
41. Gf L, Raj A, Alfama G, Turque N, Hassani Z, Alegria-Prevot O, et al. Adult
neural stem cell cycling in vivo requires thyroid hormone and its alpha
receptor. FASEB J. 2005;19:863–5.
42. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J
Med. 2001;344(7):501–9.
43. Lüesse H-G, Roskoden T, Linke R, Otten U, Heese K, Schwegler H.
Modulation of mRNA expression of the neurotrophins of the nerve growth
factor family and their receptors in the septum and hippocampus of rats
after transient postnatal thyroxine treatment I. Expression of nerve growth
factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin
4 mRNA. Exp Brain Res. 1998;119(1):1–8.
44. Campolo M, Genovese T, Impellizzeri D, Ahmad A, Cornelius C, Cuzzocrea S,
et al. Post-ischemic thyroid hormone treatment in a rat model of acute
stroke. FASEB J. 2013;27(1):662.17.
45. Camboni D, Roskoden T, Schwegler H. Effect of early thyroxine treatment on
brain-derived neurotrophic factor mRNA expression and protein amount in the
rat medial septum/diagonal band of Broca. Neurosci Let. 2003;350(3):141–4.
46. Vaidya V, Castro M, Pei Q, Sprakes M, Grahame-Smith D. Influence of thyroid
hormone on 5-HT 1A and 5-HT 2A receptor-mediated regulation of
hippocampal BDNF mRNA expression. Neuropharmacology. 2001;40(1):48–56.
47. Koibuchi N, Fukuda H, Chin WW. Promoter-Specific Regulation of the Brain-
Derived Neurotropic Factor Gene by Thyroid Hormone in the Developing
Rat Cerebellum 1. Endocrinology. 1999;140(9):3955–61.
48. Giordano T, Pan JB, Casuto D, Watanabe S, Arneric SP. Thyroid hormone
regulation of NGF, NT-3 and BDNF RNA in the adult rat brain. Mole Brain
Res. 1992;16(3):239–45.
49. Sui L, Ren W-W, Li B-M. Administration of thyroid hormone increases reelin
and brain-derived neurotrophic factor expression in rat hippocampus in
vivo. Brain Res. 2010;1313:9–24.
50. Belakavadi M, Fondell J. Role of the mediator complex in nuclear hormone
receptor signaling. Rev Physiol Biochem Pharmacol. 2006;156:23–43.
51. Wu Y, Koenig RJ. Gene regulation by thyroid hormone. Trends Endocrinol
Metab. 2000;11(6):207–11.
52. Li Q, Sachs L, Shi Y-B, Wolffe AP. Modification of chromatin structure by the
thyroid hormone receptor. Trends Endocrinol Metab. 1999;10(4):157–64.
53. Rami A, Krieglstein J. Thyroxine attenuates hippocampal neuronal damage
caused by ischemia in the rat. Life Sci. 1992;50(9):645–50.
54. Losi G, Garzon G, Puia G. Nongenomic regulation of glutamatergic
neurotransmission in hippocampus by thyroid hormones. Neuroscience.
2008;151(1):155–63.
55. Davis PJ. Integrated nongenomic and genomic actions of thyroid hormone
on blood vessels. Curr Opin Endocrinol Diabetes Obes. 2011;18(5):293–4.
56. Distefano III JJ, Jang M, Malone T, Broutman M. Comprehensive Kinetics of
Triiodothyronine Production, Distribution, and Metabolism in Blood and
Tissue Pools of the Rat Using Optimized Blood-Sampling Protocols.
Endocrinology. 1982;110(1):198–213.
57. Zhang Y, Meyer MA. Clinical analysis on alteration of thyroid hormones in
the serum of patients with acute ischemic stroke. Stroke Res Treat. 2010;
2010. doi: 10.4061/2010/290678
58. Drover VA, Agellon LB. Regulation of the human cholesterol 7α-hydroxylase
gene (CYP7A1) by thyroid hormone in transgenic mice. Endocrinology.
2004;145(2):574–81.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mokhtari et al. DARU Journal of Pharmaceutical Sciences  (2017) 25:4 Page 11 of 11
